Sorrento Therapeutics Inc. [SRNE] Stock trading around $1.45 per share: What’s Next?


Sorrento Therapeutics Inc. [NASDAQ: SRNE] price plunged by -8.23 percent to reach at -$0.13. The company report on May 18, 2022 that Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in subjects with moderate to severe acute lower back pain (LBP). The trial will enroll 80 patients with acute lower back pain.

SP-103 is a pharmacologically validated drug candidate and has the potential as a best-in-class agent of pain treatment for low back pain without the limitations of current therapies, including the addictive potential of opioids.

A sum of 5727081 shares traded at recent session while its average daily volume was at 9.59M shares. Sorrento Therapeutics Inc. shares reached a high of $1.545 and dropped to a low of $1.42 until finishing in the latest session at $1.45.

The one-year SRNE stock forecast points to a potential upside of 93.1. The average equity rating for SRNE stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Sorrento Therapeutics Inc. [SRNE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SRNE shares is $21.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SRNE stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

B. Riley Securities have made an estimate for Sorrento Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 29, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on January 21, 2021, representing the official price target for Sorrento Therapeutics Inc. stock. Previously, the target price had yet another raise from $24 to $30, while H.C. Wainwright kept a Buy rating on SRNE stock.

The Average True Range (ATR) for Sorrento Therapeutics Inc. is set at 0.14, with the Price to Sales ratio for SRNE stock in the period of the last 12 months amounting to 9.83. The Price to Book ratio for the last quarter was 2.16, with the Price to Cash per share for the same quarter was set at 0.70.

SRNE Stock Performance Analysis:

Sorrento Therapeutics Inc. [SRNE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.64. With this latest performance, SRNE shares dropped by -17.61% in over the last four-week period, additionally sinking by -76.54% over the last 6 months – not to mention a drop of -79.46% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRNE stock in for the last two-week period is set at 40.97, with the RSI for the last a single of trading hit 42.17, and the three-weeks RSI is set at 39.52 for Sorrento Therapeutics Inc. [SRNE]. The present Moving Average for the last 50 days of trading for this stock 1.9024, while it was recorded at 1.5420 for the last single week of trading, and 4.8287 for the last 200 days.

Insight into Sorrento Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Sorrento Therapeutics Inc. [SRNE] shares currently have an operating margin of -695.68 and a Gross Margin at +67.54. Sorrento Therapeutics Inc.’s Net Margin is presently recorded at -809.63.

Return on Equity for this stock declined to -351.23, with Return on Assets sitting at -62.45.

Sorrento Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sorrento Therapeutics Inc. go to 37.00%.

Sorrento Therapeutics Inc. [SRNE] Insider Position Details

There are presently around $204 million, or 33.60% of SRNE stock, in the hands of institutional investors. The top three institutional holders of SRNE stocks are: STATE STREET CORP with ownership of 33,960,884, which is approximately 132.676% of the company’s market cap and around 5.79% of the total institutional ownership; BLACKROCK INC., holding 22,034,889 shares of the stock with an approximate value of $34.81 million in SRNE stocks shares; and VANGUARD GROUP INC, currently with $25.12 million in SRNE stock with ownership of nearly 1.33% of the company’s market capitalization.

Positions in Sorrento Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 125 institutional holders increased their position in Sorrento Therapeutics Inc. [NASDAQ:SRNE] by around 42,379,820 shares. Additionally, 78 investors decreased positions by around 6,084,857 shares, while 68 investors held positions by with 80,354,809 shares. The mentioned changes placed institutional holdings at 128,819,486 shares, according to the latest SEC report filing. SRNE stock had 40 new institutional investments in for a total of 5,398,958 shares, while 39 institutional investors sold positions of 3,609,075 shares during the same period.